Next Article in Journal
Identification of Chalcone Isomerase Family Genes and Roles of CnCHI4 in Flavonoid Metabolism in Camellia nitidissima
Previous Article in Journal
Identification of Immune Infiltration and the Potential Biomarkers in Diabetic Peripheral Neuropathy through Bioinformatics and Machine Learning Methods
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomolecules
Volume 13
Issue 1
10.3390/biom13010040
biomolecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Regulatory Mechanism of miR-574-5p Expression in Cancer

by
Wei Huang
†,
Yifan Zhao
†,
Zhengyi Xu
,
Xiaoyue Wu
,
Mingxin Qiao
,
Zhou Zhu
* and
Zhihe Zhao
*
State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Biomolecules 2023, 13(1), 40; https://doi.org/10.3390/biom13010040
Submission received: 19 November 2022 / Revised: 21 December 2022 / Accepted: 22 December 2022 / Published: 26 December 2022
Browse Figures
Review Reports Versions Notes

Abstract

:
MicroRNAs (miRNAs) are a group of small, single-stranded, non-coding RNAs approximately 22 nucleotides in length. The dysregulation of miRNAs has been widely investigated in various pathological processes, including tumorigenesis, providing a biomarker for cancer diagnosis and prognosis. As a member of the miRNA family, miR-574-5p is located on the human chromosome 4p14 and is highly correlated with a high incidence of human cancers. Functional pathways as well as underlying novel mechanisms upregulate or downregulate miR-574-5p, which plays an important regulatory role in tumorigenesis and progression. In this review, we systematically summarize the context-dependent implications of miR-574-5p and review differences in miR-574-5p expression in cancer. We also investigate the intricate functions exerted by miR-574-5p in diverse pathological processes and highlight regulatory pathways, networks, and other underlying novel mechanisms. The clinical applications of miR-574-5p as a diagnostic biomarker, prognostic biomarker, and therapeutic mechanism are also discussed in this paper. On this basis, we anticipate that miR-574-5p will be a promising and effective biomarker and therapeutic target.

1. Introduction

MicroRNAs (miRNAs) are a group of small, single-stranded, non-coding RNAs approximately 22 nucleotides in length [1]. Since firstly discovered in the nematode C. elegans. in 1993 [2], thousands of miRNA genes have been annotated in diverse species, including humans. Either residing in the intergenic or intragenic regions of the genome, miRNAs account for approximately 1-5% of the human genome and regulate over 30% of protein-coding, survival-related genes based on predictions [3,4]. In recent years, a large body of literature has accrued regarding their critical role in post-transcriptionally regulating gene expression, mainly acting through binding to the 3’-untranslated regions (UTRs) of messenger RNAs (mRNAs). According to the different degree and nature of complementarity between miRNA sequences and the target mRNA 3’UTRs, the latter translation could be completely degraded or partially inhibited, resulting in delicate modulations of a variety of fundamental cellular and physiological activities, such as cell proliferation, embryogenesis, and development [5,6]. With advances in experimental and computational methodologies in the miRNA research field, the dysregulation of miRNAs has been widely investigated in various pathological processes, including tumorigenesis, rendering them a promising diagnostic and therapeutical target in the future [7].
Recently, a growing number of studies have highlighted the significant role of miR-574-5p, a member of the miRNA family, in multiple human diseases. Human miR-574-5p (has-miR-574-5p) is encoded by mir574 (gene ID: 693159), which is located on the human chromosome 4p14 and is generated in a multi-step process (Figure 1). Transcription begins with RNA polymerase II, which produces an initial long transcription chain called pri-miRNA. Unlike the canonical miR biogenesis pathway, pri-miRNAs can be spliced and debranched into pre-miRNA hairpins that are suitable for Dicer cleavage, thus bypassing the microprocessor [8,9,10]. Upon being exported to the cytoplasm by exportin-5 (XPO5), pre-miRNAs are cleaved by two RNases and turned into an RNA duplex of approximately 22 nucleotides [11]. In the case of miR-574-5p, the strand originating from the 5’ side of the pre-miRNA (thus annotated with the suffix -5p) is selectively loaded on the argonaute protein (AGO) to form the miRNA-induced silencing complex (RISC) [12]. Unlike the usually degraded undominated strand, the 3’ strand of miR-574 still gives rise to the functional miR-574-3p counterpart, and the 5p/3p ratio reportedly contributes to some pathologies [13,14].
In this review, we discuss the context-dependent implications of miR-574-5p in a variety of diseases, including some of the most fatal cancers and other diseases, such as cardiovascular and neurological problems. Additionally, as miRNAs have been recognized as a control hub or node in the intricate regulatory network, we focus on how it works and is regulated, highlighting the downstream targets and functional pathways of miR-574-5p dysregulation in cancer, as well as the typical non-coding RNA network. Some novel findings of its regulatory mechanism in cancer are also noted in an attempt to fuel our understanding of the underlying mechanisms of miRNA functions and regulations. In addition, although still in infancy, the promising clinical potential of miR-574-5p also deserves attention, as emerging studies have shed light on its value as a biomarker and therapeutic target.

2. The Context-Dependent Role of miR-574-5p in Cancer

Dysregulated miR-574-5p has been found in all pathological processes of tumorigenesis, including cancer cell proliferation, migration, invasion, metastasis, apoptosis, epithelial-mesenchymal transition, and angiogenesis (Figure 2). However, numerous studies have found that the role of miR-574-5p is significant but also controversial, acting as both a tumor suppressor and oncogene according to the tumor type and associated pathways. Therefore, its implication in cancer might be context-specific, which we further discuss below.

2.1. Lung Cancer

With an estimated 1.8 million deaths worldwide, lung cancer is the leading cause of cancer-related death, remaining one of the most severe global health issues [15,16]. Histologically, lung cancer can generally be divided into two major classes: small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC). The latter, which accounts for approximately 85% of all cases, includes subtypes such as lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) [17]. Despite all the clinical progress during these years, the molecular heterogeneity, high relapse rate, and overall low survival rate of lung cancer continue to spur research into the underlying pathological mechanisms, diagnosis, and therapies, where miR-574-5p might play a role.
Early in 2012, a study by Li. et al. characterized the oncogenic role of miR-574-5p in lung cancer [18]. miRNA array analysis showed that it was the most upregulated miRNA in human lung cancer cells under Toll-like receptor 9 (TLR9) signaling. Experimental downregulation of miR-574-5p both in vitro and in vivo inhibited enhanced tumor progression, further validating its involvement in lung cancer. As the contradictory functions of miR-574-5p have been evidenced by a growing number of studies this year, it may be speculated that miR-574-5p plays a context-dependent role on different types of lung cancer, both promoting and inhibiting oncogenesis.
On the one hand, the majority of studies indicated that miR-574-5p was a promoter of NSCLC development. Research by Zhou et al. indicated that miR-574-5p was involved in the progression and metastasis of NSCLC, as it enhanced the migration and invasion of cancer cells mainly through inhibiting the expression of its downstream target, protein tyrosine phosphatase receptor type U (PTPRU) [19]. Similarly, Rho family GTPase 3 (RND3) has also been recognized as a downstream target of miR-574-5p, the inhibition of which significantly accelerated apoptosis and suppressed adenocarcinoma progression [20]. In addition, recent studies have noted that miR-574-5p-activated prostaglandin E2 (PGE2) synthesis, a crucial inflammatory lipid mediator, was also related to NSCLC development in an intricate manner [21].
On the other hand, studies with SCLC, a less predominant but also significant subtype of lung cancer, mostly reported miR-574-5p as a tumor suppressor through the non-coding RNA network. As indicated in two studies, miR-574-5p partially exerted a protective effect as a long non-coding RNA (lncRNA) sponge, antagonizing the oncogenic lncRNA HOTTIP (HOXA transcript at the distal tip) and affecting the expression of downstream targets, such as enhancer of zeste homolog 1 (EZH1) protein and vimentin (VIM), ultimately alleviating SCLC cell growth, proliferation, and also EMT [22,23]. However, as another study showed miR-574-5p facilitated metastasis of SCLC [24], more research is required.

2.2. Thyroid Cancer

Thyroid cancer, the most common malignant tumor of the endocrine system, includes papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), anaplastic thyroid carcinoma (ATC), and medullary thyroid carcinoma (MTC), with PTC being predominant among all subtypes [25,26]. Although most cases of PTC have a better prognosis than other types of malignant tumors, cervical lymph node metastasis can occur at the beginning of diagnosis and severely influences the 10-year survival rate [27,28]. Other subtypes, such as FTC, despite accounting for a smaller proportion of thyroid cancer cases, has higher distant metastasis rates and worse prognosis [29]. Therefore, it is of great clinical significance to understand the underlying pathogenic mechanism of thyroid cancer, where miR-574-5p serves as a candidate oncogene.
In 2013, a study found that papillary thyroid carcinoma susceptibility candidate 3 (PTCSC3), a newly identified lncRNA, could selectively bind with miR-574-5p. Significant growth inhibition, cell cycle arrest, and increased apoptosis were observed in three pathological types of thyroid cancer cells with PTCSC transfection [30]. Following this axis, another study further confirmed that PTCSC/miR-574-5p mediated the PTC-1 cell cycle through targeting suppressor of cancer cell invasion (SCAI), thus promoting the proliferation and migration of PTC via Wnt/β-catenin pathway [31]. In addition to SCAI, Zhang et al. demonstrated that the disrupted cell cycle and apoptosis induced by miR-574-5p were associated with another target, quaking proteins (QKIs) [32]. Additionally, fork head box N3 (FOXN3), a key cell cycle regulator and transcriptional tumorigenesis suppressor, was also identified as a direct target of miR-574-5p in thyroid cancer progression [33,34]. Conclusively, the oncogenic function of miR-574-5p in thyroid cancer was closely related to the cell cycle and Wnt/β-Catenin signaling, and novel targets remain to be identified.

2.3. Breast Cancer (BC)

Breast cancer is the most common cancer type in women, and female breast cancer has already surpassed lung cancer as the most diagnosed cancer, with an estimated 2.3 million new cases (11.7%) according to statistics in 2020 [15]. As a heterogeneous disease, breast cancer can be divided into 3 major subtypes in terms of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2) [35]. Triple-negative BC (TNBC), defined as the absence of all three molecular targets, accounts for approximately 15% of BC cases and relates to worse therapeutic response to chemotherapy or hormone therapy, as well as a higher risk of distant relapse and poorer prognosis compared with other types [36,37,38]. However, the underlying pathogenic mechanisms of TNBC remain elusive.
In recent years, the protective role of miR-574-5p in breast cancer, especially TNBC, has been gradually brought to light. A study by Zhang et al. reported that miR-574-5p could repress TNBC cell proliferation, migration, and epithelial-mesenchymal transition (EMT) in vitro while reducing tumor growth and metastasis in vivo. It was demonstrated that miR-574-5p could simultaneously target SRY (sex-determining region Y)-box 2 (SOX2), B-cell lymphoma/leukemia 11A (BCL11A), and thus inhibit the SKIL/transcriptional co-activator with PDZ-binding motif (TAZ)/connective tissue growth factor (CTGF) axis to regulate malignant phenotypes in TNBC [39].
As TNBC tends to metastasize distantly to specific organs, such as the lungs, a high level of miR-574-5p inhibited the migration and invasion abilities in lung-metastatic TNBC cells, whereas its knockdown resulted in enhanced metastasis performance [40,41]. Further experiments demonstrated that miR-574-5p was the shared miRNA for the upstream linc-ZNF469-3 and downstream target ZEB1, highlighting the role of linc-ZNF469-3/miR-574-5p/ZEB1 in TNBC lung metastasis.

2.4. Gastric Cancer (GC)

As the third leading cause of cancer-related deaths worldwide, gastric cancer represents a huge clinical challenge due to its aggressive characteristics and poor prognosis [42]. Although relatively fewer studies have focused on the role of miR-574-5p in gastric cancer, the existing literature has already shed light on some novel mechanisms of miRNAs pathogenic functions.
For instance, a study in 2020 first elucidated that miR-574-5p engaged in gastric cancer by promoting angiogenesis, a crucial pathological process for tumor growth, development, and metastasis [43,44,45]. It was found that miR-574-5p was upregulated in response to hypoxic conditions both in vitro and in vivo, and inhibition of miR-574-5p resulted in decreased endothelial growth factor A (VEGFA) expression, as well as reduced viability, migration, invasion, and tube formation of human umbilical vein endothelial cell lines (HUVECs). Unexpectedly, this promotion was achieved through activation of 44/42 mitogen-activated protein kinases (MAPKs) by mir574-targeted inhibition of protein tyrosine phosphatase non-receptor type 3 (PTPN3), revealing another way to achieve VEGFA regulation besides hypoxia-inducible factor-1α (HIF-1α) stability [46].
In addition, as miR-574-3p, the counterpart of miR-574-5p, also contributed to angiogenesis in gastric cancer development by targeting cullin2, the aberrant ratio of 5p/3p is another critical player in gastric cancer, as revealed by Zhang et al. in 2019 [13,43]. Their findings indicated that although derived from the same precursor, miR-574-5p and 3p arms were inversely expressed in patients and exerted opposite effects on gastric carcinogenesis with different downstream targets, QKI6 and ACVR1B, respectively. Based on the target RNA directed miRNA degradation (TDMD) theory, these authors revealed that the upregulated 5p/3p ratio, namely miR-574 arm-imbalance, was partially attributed to the dynamic expression of the highly complementary targets of miRNAs, and in turn exacerbated gastric cancer progression, correlating with poorer prognosis with advanced TNM stages.
In addition, as environmental carcinogens are an important etiologic factor in gastric carcinogenesis, miR-574-5p was also shown to be involved in environmental carcinogen-induced gastric cancer by interfering with tumor-suppressive lncRNA LOC101927497, thus promoting the proliferation and migration of N-methyl-N′-nitro-N-nitrosoguanidine (MNNG)-induced malignantly transformed human gastric epithelial cells [47,48].

2.5. Colorectal Cancer (CRC)

Although CRC remains the second most common cause of cancer death in the United States, advancements in screening and detection techniques, as well as the understanding of risk factors, pathogenesis, and precursor lesions, have resulted in the reduction of morbidity and mortality of CRC [49,50]. Intriguingly, previous reports about miR-574-5p involvement in CRC demonstrated controversial results.
In 2013, Ji et al. first unraveled the oncogenic role of miR-574-5p in CRC. In CRC tissue from both C57BL/6-Apcmin+ mice and clinical patients, the expression of miR-574-5p was shown to be significantly upregulated, which was inversely correlated with the Quaking family of RNA-binding proteins (Qki) and positively correlated with β-catenin [51]. Further experiments confirmed this functional axis, revealing that miR-574-5p could negatively regulate Qki6/7 via interactions with miRNA recognition elements (MREs) on the corresponding 3’UTRs, thus exerting oncogenic effects such as increased CRC cell proliferation, invasion, and migration, decreased differentiation, and cell cycle exit. These oncogenic effects were further investigated in another study in 2019, which indicated that miR-574-5p accelerated the migration and invasion of CRC cells by targeting downstream calcium-binding and coiled-coil domain 1 (CALCOCO1), whereas the non-coding RNA LINC00052 inhibited CRC metastasis via sponging miR-574-5p and modulating CALCOCO1 expression [52].
However, a contradictory conclusion was drawn in another report, demonstrating that hsa-miR-574-5p played a suppressive role in colorectal cancer liver metastasis by negatively directing MACC-1 expression [53]. In addition, different lncRNA networks may act divergently in the same disease. Li et al. reported the protective effects of miR-574-5p for CRC development through regulation of the lncRNA MFI2-AS1/miR-574-5p/MYCBP axis [54]. Conclusively, the complexity of the miR-574-5p regulatory network calls for greater exploration and clearer elucidation in this field (Table 1).

2.6. Others

There is growing evidence recognizing miR-574-5p as a potential oncogene in esophageal squamous cell carcinoma (ESCC). In 2020, a study by Guo et al. found that downregulated miR-574-5p could inhibit ESCC cell proliferation and promote apoptosis via directly targeting Zinc finger protein 70 (ZNF70), and these functions were correlated with reactive oxygen species (ROS) generation and MAPK pathways [55]. Unregulated miR-574-5p has been found in ESCC tumor tissues according to other studies as well [56,57].
In addition, the tumor-promotive role of miR-574-5p has been revealed in other types of cancer, such as cervical cancer and nasopharyngeal carcinoma [31,33], respectively targeting QKI and FOXN3, with which interactions were previously discussed in gastric cancer, CRC, and thyroid cancer [13]. Conversely, some reports have identified miR-574-5p as a tumor-suppressor in some relatively rare tumors, such as glioma and chordoma.
In conclusion, given disease-context effects, numerous functional targets and pathways, intricate regulatory networks, and elusive molecular mechanisms of miR-574-5p are involved in cancer incidence, progression, and metastasis, and more in-depth studies are needed in the future (Table 2).

3. The Functional Pathways and Regulatory Mechanisms of miR-574 in Cancer

As discussed above, a plethora of studies have indicated the involvement of miR-574-5p in a variety of cancers through targeting and interacting with diverse targets (Figure 3). Here, we specifically summarize some of the most extensively studied functional pathways of miR-574-5p in cancer in order to fuel our understanding the role of miRNAs in tumorigenesis and progression.

3.1. Typical Functional Pathways of miR-574-5p in Cancer

3.1.1. Wnt/β-Catenin Pathway

The Wnt/β-catenin signaling pathway, as the canonical β-catenin-dependent Wnt signaling pathway, refers to a family of conserved signaling proteins that are involved in many basic physiological processes, such as cell survival, proliferation, apoptosis, and tissue homeostasis. It was demonstrated that dysregulation of the Wnt/β-catenin contributes to cancer development and progression, with accumulating evidence shedding light on its activation in miR-574-5p-promoted tumorigenesis. Based on current research, as some protein-coding RNAs targeted by miR-574-5p, such as QKI, PTPRU, SCAI, and FOXN3, are negative regulators of the Wnt/β-catenin pathway, miR-574-5p overexpression is capable of suppressing these proteins and activating β-catenin signaling in diverse cancer types, including SCLC, NSCLC, CRC, thyroid cancer, and cervical cancer.

3.1.2. MAPK Pathway

In addition to the extensively investigated Wnt pathway, some latest studies also identified the mitogen-activated protein kinase (MAPK) pathway as a player in miR-574-5p’s tumorigenic function. As a series of protein Ser/Thr kinases that perform transmembrane signal transduction, the MAPK pathway regulates diverse basic cellular functions in almost all eukaryotic cells [58,59]. As previously mentioned, through directly inhibiting PTPN3, a protein tyrosine phosphorylase capable of removing the phosphate group on the phosphorylated tyrosine residue of kinases, miR-574-5p promoted angiogenesis and tumorigenesis in gastric cancer with an increased level of phosphorylation of 44/42 MAPKs [43,60]. However, a 2020 report revealed that miR-574-5p was a contributor to ESCC development via inhibition of the MAPK pathway [55]. It was found that downregulating miR-574-5p could induce the activation of JNK, ERK, and p38 MAPK in a ROS-dependent manner, as MAPKs serve as one of the major ROS-sensitive signal-transducing pathways and upstream signals for apoptosis initiation [61,62]. In consideration of the complexity of the MAPK pathway, more in-depth investigations of the MAPK pathway in miR-574-5p-regulated tumorigenesis are required.

3.2. Other Novel Mechanisms of miR-574-5p Regulation in Tumorigenesis

3.2.1. Arm-Imbalance

In addition to the functional pathways and ceRNA network mentioned above, emerging literature has provided some advanced insight into the underlying mechanisms of miR-574-5p in recent years. Among them, the arm-imbalance between miR-574-5p and 3p is a novel mechanism that underlies the progression of gastric cancer. It was found that although derived from the same precursor miR-574, the two strands played reverse roles in GC development with distinct downstream targets, and upregulation of the 5p/3p ratio was correlated with aggressive disease stage [13].
One possible theoretical explanation for the imbalanced 5p/3p ratio in gastric carcinogenesis is the target RNA-directed miRNA degradation (TDMD), which means the highly complementary targeted RNAs of miRNAs could trigger their degradation [63,64]. As validated by various experimental methods in the report, several 5p-targeted tumor-suppressive mRNAs were downregulated during carcinogenesis, thus increasing the miR-574-5p level, whereas the miR-574-3p level decreased when its target level were raised. The broken target-miRNA homeostasis in GC exerted positive feedback, as upregulated miR-574-5p further inhibited more tumor suppressive targets while the decreased counterpart 3p promoted oncogenes, synergistically accelerating GC progression with more slanted imbalance. With this finding in mind, instead of merely focusing on miR-574-5p, the maintenance and re-modification of miR-574-targeted homeostasis may be of greater significance for cancer treatments in the future.

3.2.2. Origin-Dependent Role of miR-574-5p

Another interesting finding is that the subcellular distribution of miR-574-5p may also serve as a critical regulator for miRNA functions in pathogenesis. Specifically, Saul et al. revealed in 2019 that miR-574-5p could act as an RNA decoy to CUG RNA-binding protein 1 (CUGBP1), thus inducing microsomal prostaglandin E synthase-1 (mPGES-1) expression with enhanced alternative splicing and generation of an mPGES-1 3’UTR isoform, finally promoting tumor growth in vivo [65,66]. However, a recent study in 2021 contradicted this conclusion, suggesting the effects were only related to intracellular miR-574-5p, whereas those derived from small extracellular vesicles (sEV) exhibited the opposite effects, thus downregulating mPGES-1 and the PGE2 level. The seemingly contradictory effect depends on miRNA transfer via sEV to the novel subcellular location, enabling sEV-derived miR-574-5p to activate endosomal Toll-like receptors (TLR) 7/8 in a cell-specific behavior that is uniquely limited to adenocarcinoma [67]. They also identified that the combination of intracellular and sEV-derived miR-574-5p delicately regulated PGE2-levels through a feedback loop since inflammatory PGE2 induced by the tumor environment could trigger miR-574-5p sorting into sEV and upregulate the sEV-derived miR-574-5p level. Conclusively, it was found that the same miRs could exert distinct functions in tumorigenesis based on their subcellular localization for the first time.

4. miR-574-5p in Other Diseases

Significantly, despite most attention having been focused on the role of miR-574-5p in cancer, its implication in pathogenesis is far beyond only cancer, involving a wide range of other non-cancerous diseases of different systems.
For example, several studies discussed the dual effects of miR-574-5p in cardiovascular disease. It was found that miR-574-5p expression was upregulated in both the sera and vascular smooth muscle cells (VSMCs) of coronary artery disease (CAD) patients, and that overexpression promoted cell proliferation and inhibited apoptosis by directly targeting the ZDHHC14 gene. As the aberrant proliferation of VSMCs contributes to atherosclerotic plaque formation, a salient pathogenic factor of CAD, miR-574-5p was proven as a CAD-related factor involved in disease development [68]. Additionally, another study revealed the correlation between miR-574-5p and cardiac fibrosis after myocardial infarction (MI). Through binding to the 3’UTR of ARID3A, miR-574-5p promoted the fibroblast-to-myofibroblast conversion of human cardiac fibroblasts (HCFs) attributed to TGF-β-induced cardiac fibrosis [69].
Moreover, in addition to serving as a pathogenic factor, miR-574-5p also exerts cardioprotective effect in the heart. A study by Wu et al. demonstrated that both 5p and 3p strands could be induced under pathogenic cardiac stress [70]. The experiments showed that genetic knockout or exogenous injection of miR-574 significantly influenced the disease phenotype, resulting in exacerbated or attenuated pathological cardiac remodeling, respectively. Mechanistically, the protective effect depended on its downstream target FAM210A (family with sequence similarity 210 member A), which interacted with mitochondrial translation elongation factor EF-Tu and modulated mitochondrial-encoded protein expression, a key player in normal cardiac functions [71].
Similarly, the protective role of miR-574-5p was also investigated in other systems, such as the respiratory [72], urinary [73], digestive [74,75], and nervous systems [76]. For instance, a study in 2020 illustrated that, through targeting HMGB1 (high-mobility group box-1), a key cytokine that mediates the response to inflammation, injury, and infection, miR-574-5p evidently alleviated acute respiratory distress syndrome (ARDS) [72]. In ARDS context, the miR-574-5p level was upregulated upon LPS stimulation via TLR/NF-κB–dependent pathways, whereas overexpression of miR-574-5p suppressed LPS-induced inflammatory responses and inhibited the activation of NF-kB signaling and the NLRP3 inflammasome through HMGB1 inhibition. Further, researchers found that miR-574-5p could protect against neuroinflammation, as overexpressed miR-574-5p in the hippocampal region could decrease the targeted BACE1 expression, and therefore restored synaptic function, improved spatial memory, and learning impaired by PM2.5 exposure.
Finally, the role of miR-574-5p as a pathogenic factor in some less discussed diseases should not be overlooked. For instance, two studies focused on the implication of miR-574-5p in preeclampsia, a hypertensive pregnancy disorder that affects 3–5% of pregnancies and is characterized by high blood pressure, proteinuria, and maternal organ dysfunction [77]. It was revealed that overexpression of miR-574-5p in preeclampsia endothelial cells significantly weakened the endothelial wound healing capacity through inhibition of downstream expression of SLC31A1, a key encoding gene for membrane copper transport. In this way, aberrantly upregulated miR-574-5p disrupted endothelial cell proliferation and migration by limiting copper transportation, which may contribute to the antiangiogenic environment in preeclampsia. Moreover, another study found that miR-574-5p contributed to preeclampsia development through interaction with the lncRNA AGAP2-AS1 [78]. Growing evidence has also shed light on its role in other diseases, such as schizophrenia [79], intervertebral disc degeneration [80], gestational diabetes mellitus [81], and rheumatoid arthritis [82], with more exploration required.

5. Clinical Applications of miR-574-5p

As noted above, accumulating evidence has revealed the close association between miR-574-5p and various disease developments, especially in multiple cancers, which may support the broad clinical application of miR-574-5p in the future. Some studies have already validated miR-574-5p as a plausible diagnostic or prognostic biomarker, while other reports exploring the underlying molecular mechanisms have suggested its role as a promising therapeutic target, although these studies are in their infancy (Table 3).

5.1. Diagnostic Biomarker

Circulating miRNAs have been long recognized as an ideal type of biomarker for their high availability and stability [83]. As they are widely distributed in bodily fluids, such as blood, serum urine, and saliva, and resistant to degradation by endogenous ribonuclease, miRNAs may offer an economical, sensitive, and non-invasive method for human disease diagnosis [84].
Most studies in this field have highlighted the diagnostic value of miR-574-5p in lung cancer, where current tools such as computed tomography (CT) screening still exhibit obvious setbacks [85]. For instance, a report in 2020 found that exosomal miR-574-5p levels varied significantly not only between early-stage lung adenocarcinoma patients and healthy controls, but also between pre- and post-surgery patients. With a combination of miR-342-5p and miR-574-5p, the ROC curve displayed 0.813 (95% CI: 0.7249 to 0.9009) with sensitivity and specificity of 80.0% and 73.2% respectively [86]. Similarly, its role in distinguishing early-stage NSCLC patients has also been revealed, especially with other non-coding RNAs such as hsa-miR-1254 or lncRNA MALAT1 [87,88].
In addition to cancer, miR-574-5p also serves as a convenient diagnostic tool in various diseases, such as CAD, thoracic aortic aneurysm (TAA), and even schizophrenia (SCZ) [79,89,90]. Interestingly, as circulating miR-574-5p levels were upregulated in CAD and SCZ patients, they were significantly decreased in TAA tissues but raised in serum samples from another 28 TAA patients compared with controls, a discrepancy perhaps due to the limited statistical power of the study or by the heterogeneity of TAA pathogenesis in patients. This discrepancy also implied that although miR-574-5p has several advantages, its reliability in diagnosis still requires further confirmation.

5.2. Prognostic Biomarker

In addition, a growing number of studies have revealed the potential of miR-574-5p in prognosis predictions. For one thing, some reports have demonstrated its association with advanced stages, distant metastasis, or treatment responses in cancers including ESCC, SCLC, and BC [40,91,92]. For another, miR-574-5p also offers the capability of outcome prediction in other diseases. For instance, miR-574-5p had excellent prognostic ability for incident asthma in early childhood with an AUROC of 0.83 under vitamin D level modification [93]. Another study explored its correlation with neurological outcomes after cardiac arrest, suggesting that a higher level of circulating miR-574-5p was associated with poorer neurological outcomes in women (OR [95% CI]: 1.9 [1.09–3.45]), but not in men (OR [95% CI]: 1.0 [0.74–1.28]) [94]. Additionally, two research groups noted its prognostic role in sepsis, despite the seemingly contradictory results. While Liu et al. indicated that down-regulated miR-574-5p was correlated with the onset of acute kidney injury in sepsis patients [95], Wang et al. found that serum miR-574-5p level was associated with death from sepsis, with a significantly higher level in sepsis survivors [96].
Given the inconsistent findings, some other studies noted that its prognostic value was skeptical, at least in certain specific diseases. For example, although the aberrant upregulation of miR-574-5p could serve as a diagnostic biomarker for colorectal cancer, its association with TNM stage or lymph node status was insufficient, mainly because its oncogenic role primarily occurred at the early stages [51]. Similarly, Zhou et al. found that serum miR-574-5p expression was not a predictor for progression of advanced NSCLC, indicating that its role as a prognostic biomarker should be further validated in a larger population [19].

6. Conclusions

A large body of literature has accrued on the context-dependent role of miR-574-5p in multiple cancers and other systemic diseases, suggesting its great potential in clinical settings. Functional pathways, networks, and underlying novel mechanisms upregulate or downregulate miR-574-5p, which contribute to tumorigenesis. With the rapid development of nucleic acid therapeutics applied to clinical treatment, miR-574-5p and its related regulatory factors may become potential drug therapeutic targets, providing a valuable breakthrough for cancer treatment and intervention.
In this review, we summarized the intricate functions exerted by miR-574-5p in diverse pathological processes and highlighted the regulatory pathways, networks, and other underlying novel mechanisms. It is noteworthy that although emerging findings have shed light on its therapeutic value as a non-invasive diagnostic and prognostic biomarker, elucidation and further validation are still needed for future clinical translation.

Author Contributions

Z.Z. (Zhihe Zhao) and Z.Z. (Zhou Zhu) designed the study and reviewed the manuscript. W.H. and Y.Z. finished the majority of manuscript. Z.X. (Zhengyi Xu) and X.W. provided assist on painting figures. M.Q. reviewed the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (grant no. 82101076), the Postdoctoral Research Foundation of China (No. 2020M683334), the Research Funding from West China School/Hospital of Stomatology Sichuan University (No. RCDWJS2021-7), the Research and Develop Program from West China School/Hospital of Stomatology Sichuan University (No. RD-02-202109), and the Construction of Chengdu AI Application Development Industrial Technology Foundation Public Service Platform (2021-0166-1-2).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Saliminejad, K.; Khorram Khorshid, H.; Soleymani Fard, S.; Ghaffari, S. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J. Cell. Physiol. 2019, 234, 5451–5465. [Google Scholar] [CrossRef]
  2. Lee, R.; Feinbaum, R.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75, 843–854. [Google Scholar] [CrossRef]
  3. Iaquinta, M.R.; Lanzillotti, C.; Mazziotta, C.; Bononi, I.; Frontini, F.; Mazzoni, E.; Oton-Gonzalez, L.; Rotondo, J.C.; Torreggiani, E.; Tognon, M.; et al. The role of microRNAs in the osteogenic and chondrogenic differentiation of mesenchymal stem cells and bone pathologies. Theranostics 2021, 11, 6573–6591. [Google Scholar] [CrossRef] [PubMed]
  4. Matsuyama, H.; Suzuki, H. Systems and Synthetic microRNA Biology: From Biogenesis to Disease Pathogenesis. Int. J. Mol. Sci. 2019, 21, 132. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Bautista-Sánchez, D.; Arriaga-Canon, C.; Pedroza-Torres, A.; De La Rosa-Velázquez, I.; González-Barrios, R.; Contreras-Espinosa, L.; Montiel-Manríquez, R.; Castro-Hernándezet, C.; Fragoso-Ontiveros, V.; Álvarez-Gómez, R.M.; et al. The Promising Role of miR-21 as a Cancer Biomarker and Its Importance in RNA-Based Therapeutics. Mol. Ther. Nucleic Acids 2020, 20, 409–420. [Google Scholar] [CrossRef] [PubMed]
  6. Bernstein, E.; Kim, S.Y.; Carmell, M.A.; Murchison, E.P.; Alcorn, H.; Li, M.Z.; Mills, A.A.; Elledge, S.J.; Anderson, K.V.; Hannon, G.J. Dicer is essential for mouse development. Nat. Genet. 2003, 35, 215–217. [Google Scholar] [CrossRef] [PubMed]
  7. Esteller, M. Non-coding RNAs in human disease. Nat. Rev. Genet. 2011, 12, 861–874. [Google Scholar] [CrossRef]
  8. Ha, M.; Kim, V. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014, 15, 509–524. [Google Scholar] [CrossRef]
  9. Han, J.; Lee, Y.; Yeom, K.; Kim, Y.; Jin, H.; Kim, V. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 2004, 18, 3016–3027. [Google Scholar] [CrossRef] [Green Version]
  10. Havens, M.A.; Reich, A.A.; Duelli, D.M.; Hastings, M.L. Biogenesis of mammalian microRNAs by a non-canonical processing pathway. Nucleic Acids Res. 2012, 40, 4626–4640. [Google Scholar] [CrossRef]
  11. Yi, R.; Qin, Y.; Macara, I.; Cullen, B. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003, 17, 3011–3016. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Medley, J.; Panzade, G.; Zinovyeva, A. microRNA strand selection: Unwinding the rules. Wiley Interdiscip. Rev. RNA 2021, 12, e1627. [Google Scholar] [CrossRef] [PubMed]
  13. Zhang, Z.; Pi, J.; Zou, D.; Wang, X.; Xu, J.; Yu, S.; Zhang, T.; Li, F.; Zhang, X.; Zhao, H.; et al. microRNA arm-imbalance in part from complementary targets mediated decay promotes gastric cancer progression. Nat. Commun. 2019, 10, 4397. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Yao, P.; Wu, J.; Lindner, D.; Fox, P. Interplay between miR-574-3p and hnRNP L regulates VEGFA mRNA translation and tumorigenesis. Nucleic Acids Res. 2017, 45, 7950–7964. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
  16. Herbst, R.; Morgensztern, D.; Boshoff, C. The biology and management of non-small cell lung cancer. Nature 2018, 553, 446–454. [Google Scholar] [CrossRef]
  17. Stapelfeld, C.; Dammann, C.; Maser, E. Sex-specificity in lung cancer risk. Int. J. Cancer 2020, 146, 2376–2382. [Google Scholar] [CrossRef]
  18. Li, Q.; Li, X.; Guo, Z.; Xu, F.; Xia, J.; Liu, Z.; Ren, T. MicroRNA-574-5p was pivotal for TLR9 signaling enhanced tumor progression via down-regulating checkpoint suppressor 1 in human lung cancer. PloS ONE 2012, 7, e48278. [Google Scholar] [CrossRef] [Green Version]
  19. Zhou, R.; Zhou, X.; Yin, Z.; Guo, J.; Hu, T.; Jiang, S.; Liu, L.; Dong, X.; Zhang, S.; Wu, G. MicroRNA-574-5p promotes metastasis of non-small cell lung cancer by targeting PTPRU. Sci. Rep. 2016, 6, 35714. [Google Scholar] [CrossRef] [Green Version]
  20. Jiang, W.; He, Y.; Ma, Z.; Zhang, Y.; Zhang, C.; Zheng, N.; Tang, X. hsa_circ_0008234 inhibits the progression of lung adenocarcinoma by sponging miR-574-5p. Cell Death Discov. 2021, 7, 123. [Google Scholar] [CrossRef]
  21. Jakobsson, P.; Thorén, S.; Morgenstern, R.; Samuelsson, B. Identification of human prostaglandin E synthase: A microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. USA 1999, 96, 7220–7225. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Sun, Y.; Zhou, Y.; Bai, Y.; Wang, Q.; Bao, J.; Luo, Y.; Guo, Y.; Guo, L. A long non-coding RNA HOTTIP expression is associated with disease progression and predicts outcome in small cell lung cancer patients. Mol. Cancer 2017, 16, 162. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Sun, Y.; Yi, Y.; Gan, S.; Ye, R.; Huang, C.; Li, M.; Huang, J.; Guo, Y. miR-574-5p mediates epithelial-mesenchymal transition in small cell lung cancer by targeting vimentin via a competitive endogenous RNA network. Oncol. Lett. 2021, 21, 459. [Google Scholar] [CrossRef]
  24. Zhou, R.; Zhou, X.; Yin, Z.; Guo, J.; Hu, T.; Jiang, S.; Liu, L.; Dong, X.; Zhang, S.; Wu, G. Tumor invasion and metastasis regulated by microRNA-184 and microRNA-574-5p in small-cell lung cancer. Oncotarget 2015, 6, 44609–44622. [Google Scholar] [CrossRef] [Green Version]
  25. Nikiforov, Y. Thyroid carcinoma: Molecular pathways and therapeutic targets. Mod. Pathol. 2008, 2, S37–S43. [Google Scholar] [CrossRef] [Green Version]
  26. Molinaro, E.; Romei, C.; Biagini, A.; Sabini, E.; Agate, L.; Mazzeo, S.; Materazzi, G.; Sellari-Franceschini, S.; Ribechini, A.; Torregrossa, L.; et al. Anaplastic thyroid carcinoma: From clinicopathology to genetics and advanced therapies. Nat. Rev. Endocrinol. 2017, 13, 644–660. [Google Scholar] [CrossRef]
  27. Sugitani, I.; Fujimoto, Y.; Yamamoto, N. Papillary thyroid carcinoma with distant metastases: Survival predictors and the importance of local control. Surgery 2008, 143, 35–42. [Google Scholar] [CrossRef]
  28. Podnos, Y.; Smith, D.; Wagman, L.; Ellenhorn, J. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am. Surg. 2005, 71, 731–734. [Google Scholar] [CrossRef]
  29. Pitsava, G.; Stratakis, C.; Faucz, F. PRKAR1A and Thyroid Tumors. Cancers 2021, 13, 3834. [Google Scholar] [CrossRef] [PubMed]
  30. Fan, M.; Li, X.; Jiang, W.; Huang, Y.; Li, J.; Wang, Z. A long non-coding RNA, PTCSC3, as a tumor suppressor and a target of miRNAs in thyroid cancer cells. Exp. Ther. Med. 2013, 5, 1143–1146. [Google Scholar] [CrossRef] [PubMed]
  31. Tong, R.; Zhang, J.; Wang, C.; Li, X.; Yu, T.; Wang, L. LncRNA PTCSC3 inhibits the proliferation, invasion and migration of cervical cancer cells via sponging miR-574-5p. Clin. Exp. Pharmacol. Physiol. 2020, 47, 439–448. [Google Scholar] [CrossRef] [PubMed]
  32. Zhang, Z.; Li, X.; Xiao, Q.; Wang, Z. MiR-574-5p mediates the cell cycle and apoptosis in thyroid cancer cells via Wnt/β-catenin signaling by repressing the expression of Quaking proteins. Oncol. Lett. 2018, 15, 5841–5848. [Google Scholar] [CrossRef] [PubMed]
  33. Lin, Z.; Chen, M.; Wan, Y.; Lei, L.; Ruan, H. miR-574-5p Targets FOXN3 to Regulate the Invasion of Nasopharyngeal Carcinoma Cells via Wnt/β-Catenin Pathway. Technol. Cancer Res. Treat. 2020, 19, 1533033820971659. [Google Scholar] [CrossRef] [PubMed]
  34. Dai, Y.; Wang, M.; Wu, H.; Xiao, M.; Liu, H.; Zhang, D. Loss of FOXN3 in colon cancer activates beta-catenin/TCF signaling and promotes the growth and migration of cancer cells. Oncotarget 2017, 8, 9783–9793. [Google Scholar] [CrossRef] [Green Version]
  35. Waks, A.G.; Winer, E.P. Breast Cancer Treatment: A Review. JAMA 2019, 321, 288–300. [Google Scholar] [CrossRef]
  36. Liedtke, C.; Mazouni, C.; Hess, K.R.; André, F.; Tordai, A.; Mejia, J.A.; Symmans, W.F.; Gonzalez-Angulo, A.M.; Hennessy, B.; Green, M.; et al. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. J. Clin. Oncol. 2008, 26, 1275–1281. [Google Scholar] [CrossRef]
  37. Foulkes, W.D.; Smith, I.E.; Reis-Filho, J.S. Triple-Negative Breast Cancer. N. Engl. J. Med. 2010, 363, 1938–1948. [Google Scholar] [CrossRef] [Green Version]
  38. Denkert, C.; Liedtke, C.; Tutt, A.; von Minckwitz, G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet 2017, 389, 2430–2442. [Google Scholar] [CrossRef] [Green Version]
  39. Zhang, K.-J.; Hu, Y.; Luo, N.; Li, X.; Chen, F.-Y.; Yuan, J.-Q.; Guo, L. miR-574-5p attenuates proliferation, migration and EMT in triple-negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis. Int. J. Oncol. 2020, 56, 1240–1251. [Google Scholar] [CrossRef]
  40. Wang, P.-S.; Chou, C.-H.; Lin, C.-H.; Yao, Y.-C.; Cheng, H.-C.; Li, H.-Y.; Chuang, Y.-C.; Yang, C.-N.; Ger, L.-P.; Chen, Y.-C.; et al. A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer. Oncogene 2018, 37, 4662–4678. [Google Scholar] [CrossRef]
  41. Tseng, L.M.; Hsu, N.C.; Chen, S.C.; Lu, Y.S.; Lin, C.-H.; Chang, D.Y.; Li, H.; Lin, Y.C.; Chang, H.K.; Chao, T.C.; et al. Distant metastasis in triple-negative breast cancer. Neoplasma 2013, 60, 290–294. [Google Scholar] [CrossRef] [PubMed]
  42. Ajani, J.; D’Amico, T.; Bentrem, D.; Chao, J.; Cooke, D.; Corvera, C.; Das, P.; Enzinger, P.C.; Enzler, T.; Fanta, P.; et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. JNCCN 2022, 20, 167–192. [Google Scholar] [CrossRef] [PubMed]
  43. Zhang, S.; Zhang, R.; Xu, R.; Shang, J.; He, H.; Yang, Q. MicroRNA-574-5p in gastric cancer cells promotes angiogenesis by targeting protein tyrosine phosphatase non-receptor type 3 (PTPN3). Gene 2020, 733, 144383. [Google Scholar] [CrossRef] [PubMed]
  44. Hisano, Y.; Hla, T. Bioactive lysolipids in cancer and angiogenesis. Pharmacol. Ther. 2019, 193, 91–98. [Google Scholar] [CrossRef] [PubMed]
  45. De Sanctis, F.; Ugel, S.; Facciponte, J.; Facciabene, A. The dark side of tumor-associated endothelial cells. Semin. Immunol. 2018, 35, 35–47. [Google Scholar] [CrossRef] [PubMed]
  46. Bruick, R.; McKnight, S. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294, 1337–1340. [Google Scholar] [CrossRef] [Green Version]
  47. Luo, Y.; Liang, M.; Yao, W.; Liu, J.; Niu, Q.; Chen, J.; Liu, Z.; Li, M.; Shi, B.; Pan, J.; et al. Functional role of lncRNA LOC101927497 in N-methyl-N’-nitro-N-nitrosoguanidine-induced malignantly transformed human gastric epithelial cells. Life Sci. 2018, 193, 93–103. [Google Scholar] [CrossRef]
  48. Liabeuf, D.; Oshima, M.; Stange, D.E.; Sigal, M. Stem Cells, Helicobacter pylori, and Mutational Landscape: Utility of Preclinical Models to Understand Carcinogenesis and to Direct Management of Gastric Cancer. Gastroenterology 2022, 162, 1067–1087. [Google Scholar] [CrossRef]
  49. Siegel, R.L.; Miller, K.D.; Sauer, A.G.; Fedewa, S.A.; Butterly, L.F.; Anderson, J.C.; Cercek, A.; Smith, R.A.; Jemal, A. Colorectal cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 145–164. [Google Scholar] [CrossRef] [Green Version]
  50. Kanth, P.; Inadomi, J.M. Screening and prevention of colorectal cancer. BMJ 2021, 374, n1855. [Google Scholar] [CrossRef]
  51. Ji, S.; Ye, G.; Zhang, J.; Wang, L.; Wang, T.; Wang, Z.; Zhang, T.; Wnag, G.; Guo, Z.; Luo, Y.; et al. miR-574-5p negatively regulates Qki6/7 to impact β-catenin/Wnt signalling and the development of colorectal cancer. Gut 2013, 62, 716–726. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Yu, G.; Xiong, D.; Liu, Z.; Li, Y.; Chen, K.; Tang, H. Long noncoding RNA LINC00052 inhibits colorectal cancer metastasis by sponging microRNA-574-5p to modulate CALCOCO1 expression. J. Cell. Biochem. 2019, 120, 17258–17272. [Google Scholar] [CrossRef] [PubMed]
  53. Cui, Z.; Tang, J.; Chen, J.; Wang, Z. Hsa-miR-574-5p negatively regulates MACC-1 expression to suppress colorectal cancer liver metastasis. Cancer Cell Int. 2014, 14, 47. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Li, C.; Tan, F.; Pei, Q.; Zhou, Z.; Zhou, Y.; Zhang, L.; Wang, D.; Pei, H. Non-coding RNA MFI2-AS1 promotes colorectal cancer cell proliferation, migration and invasion through miR-574-5p/MYCBP axis. Cell Prolif. 2019, 52, e12632. [Google Scholar] [CrossRef]
  55. Han, G.L.; Wang, J.; Guo, K.; Chen, J.K.; Shang, R.X.; Jiang, T. miRNA-574-5p downregulates ZNF70 and influences the progression of human esophageal squamous cell carcinoma through reactive oxygen species generation and MAPK pathway activation. Anticancer Drugs 2020, 31, 282–291. [Google Scholar] [CrossRef]
  56. Yang, M.; Liu, R.; Sheng, J.; Liao, J.; Wang, Y.; Pan, E.; Guo, W.; Pu, Y.; Yin, L. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of esophageal squamous cell carcinoma. Oncol. Rep. 2013, 29, 169–176. [Google Scholar] [CrossRef] [Green Version]
  57. Li, J.; Han, X.; Gu, Y.; Wu, J.; Song, J.; Shi, Z.; Chang, H.; Liu, M.; Zhang, Y. LncRNA MTX2-6 Suppresses Cell Proliferation by Acting as ceRNA of miR-574-5p to Accumulate SMAD4 in Esophageal Squamous Cell Carcinoma. Front. Cell Dev. Biol. 2021, 9, 654746. [Google Scholar] [CrossRef]
  58. Widmann, C.; Gibson, S.; Jarpe, M.B.; Johnson, G.L. Mitogen-activated protein kinase: Conservation of a three-kinase module from yeast to human. Physiol. Rev. 1999, 79, 143–180. [Google Scholar] [CrossRef] [Green Version]
  59. Cargnello, M.; Roux, P.P. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol. Mol. Biol. Rev. 2011, 75, 50–83. [Google Scholar] [CrossRef] [Green Version]
  60. Hou, S.; Suresh, P.S.; Qi, X.; Lepp, A.; Mirza, S.P.; Chen, G. p38γ Mitogen-activated protein kinase signals through phosphorylating its phosphatase PTPH1 in regulating ras protein oncogenesis and stress response. J. Biol. Chem. 2012, 287, 27895–27905. [Google Scholar] [CrossRef]
  61. Takeda, K.; Matsuzawa, A.; Nishitoh, H.; Ichijo, H. Roles of MAPKKK ASK1 in stress-induced cell death. Cell Struct. Funct. 2003, 28, 23–29. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  62. Matsuzawa, A.; Ichijo, H. Redox control of cell fate by MAP kinase: Physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochim. Biophys. Acta 2008, 1780, 1325–1336. [Google Scholar] [CrossRef] [PubMed]
  63. Li, L.; Sheng, P.; Li, T.; Fields, C.J.; Hiers, N.M.; Wang, Y.; Li, J.; Guardia, C.M.; Licht, J.D.; Xie, M. Widespread microRNA degradation elements in target mRNAs can assist the encoded proteins. Genes Dev. 2021, 35, 1595–1609. [Google Scholar] [CrossRef] [PubMed]
  64. Ameres, S.L.; Horwich, M.D.; Hung, J.-H.; Xu, J.; Ghildiyal, M.; Weng, Z.; Zamore, P.D. Target RNA-directed trimming and tailing of small silencing RNAs. Science 2010, 328, 1534–1539. [Google Scholar] [CrossRef] [Green Version]
  65. Saul, M.J.; Baumann, I.; Bruno, A.; Emmerich, A.C.; Wellstein, J.; Ottinger, S.M.; Contursi, A.; Dovizio, M.; Donnini, S.; Tacconelli, S.; et al. miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. FASEB J. 2019, 33, 6933–6947. [Google Scholar] [CrossRef] [PubMed]
  66. Emmerich, A.C.; Wellstein, J.; Ossipova, E.; Baumann, I.; Lengqvist, J.; Kultima, K.; Jakobsson, P.-J.; Steinhilber, D.; Saul, M.J. Proteomics-Based Characterization of miR-574-5p Decoy to CUGBP1 Suggests Specificity for mPGES-1 Regulation in Human Lung Cancer Cells. Front. Pharmacol. 2020, 11, 196. [Google Scholar] [CrossRef] [Green Version]
  67. Donzelli, J.; Proestler, E.; Riedel, A.; Nevermann, S.; Hertel, B.; Guenther, A.; Gattenlöhner, S.; Savai, R.; Larsson, K.; Saul, M.J. Small extracellular vesicle-derived miR-574-5p regulates PGE2-biosynthesis via TLR7/8 in lung cancer. J. Extracell. Vesicles 2021, 10, e12143. [Google Scholar] [CrossRef]
  68. Lai, Z.; Lin, P.; Weng, X.; Su, J.; Chen, Y.; He, Y.; Wu, G.; Wang, J.; Yu, Y.; Zhang, L. MicroRNA-574-5p promotes cell growth of vascular smooth muscle cells in the progression of coronary artery disease. Biomed. Pharmacother. 2018, 97, 162–167. [Google Scholar] [CrossRef]
  69. Cui, J.; Qi, S.; Liao, R.; Su, D.; Wang, Y.; Xue, S. MiR-574-5p promotes the differentiation of human cardiac fibroblasts via regulating ARID3A. Biochem. Biophys. Res. Commun. 2020, 521, 427–433. [Google Scholar] [CrossRef]
  70. Wu, J.; Subbaiah, K.C.V.; Jiang, F.; Hedaya, O.; Mohan, A.; Yang, T.; Welle, K.; Ghaemmaghami, S.; Tang, W.H.W.; Small, E.; et al. MicroRNA-574 regulates FAM210A expression and influences pathological cardiac remodeling. EMBO Mol. Med. 2021, 13, e12710. [Google Scholar] [CrossRef]
  71. Couvillion, M.T.; Soto, I.C.; Shipkovenska, G.; Churchman, L.S. Synchronized mitochondrial and cytosolic translation programs. Nature 2016, 533, 499–503. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. He, B.; Zhou, W.; Rui, Y.; Liu, L.; Chen, B.; Su, X. MicroRNA-574-5p Attenuates Acute Respiratory Distress Syndrome by Targeting HMGB1. Am. J. Respir. Cell Mol. Biol. 2021, 64, 196–207. [Google Scholar] [CrossRef] [PubMed]
  73. Guo, H.; Yan, Z.; Hu, Y.; Huang, X.; Pan, C. Complement C7 is Specifically Expressed in Mesangial Cells and is a Potential Diagnostic Biomarker for Diabetic Nephropathy and is Regulated by miR-494-3p and miR-574-5p. Diabetes Metab. Syndr. Obes. 2021, 14, 3077–3088. [Google Scholar] [CrossRef]
  74. Zhou, X.; Liang, Z.; Qin, S.; Ruan, X.; Jiang, H. Serum-derived miR-574-5p-containing exosomes contribute to liver fibrosis by activating hepatic stellate cells. Mol. Biol. Rep. 2022, 49, 1945–1954. [Google Scholar] [CrossRef] [PubMed]
  75. Wu, W.; Wu, D.; Yan, W.; Wang, Y.; You, J.; Wan, X.; Xi, D.; Luo, X.; Han, M.; Ning, Q. Interferon-Induced Macrophage-Derived Exosomes Mediate Antiviral Activity Against Hepatitis B Virus Through miR-574-5p. J. Infect. Dis. 2021, 223, 686–698. [Google Scholar] [CrossRef] [PubMed]
  76. Ku, T.; Li, B.; Gao, R.; Zhang, Y.; Yan, W.; Ji, X.; Li, G.; Sang, N. NF-κB-regulated microRNA-574-5p underlies synaptic and cognitive impairment in response to atmospheric PM(2.5) aspiration. Part. Fibre Toxicol. 2017, 14, 34. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. Mol, B.W.J.; Roberts, C.T.; Thangaratinam, S.; Magee, L.A.; de Groot, C.J.M.; Hofmeyr, G.J. Pre-eclampsia. Lancet 2016, 387, 999–1011. [Google Scholar] [CrossRef]
  78. Xu, Y.; Xia, X.; Jiang, Y.; Wu, D.; Wang, S.; Fu, S.; Yang, N.; Zhang, Y.; Sun, L. Down-regulated lncRNA AGAP2-AS1 contributes to pre-eclampsia as a competing endogenous RNA for JDP2 by impairing trophoblastic phenotype. J. Cell. Mol. Med. 2020, 24, 4557–4568. [Google Scholar] [CrossRef]
  79. Davarinejad, O.; Najafi, S.; Zhaleh, H.; Golmohammadi, F.; Radmehr, F.; Alikhani, M.; Moghadam, R.H.; Rahmati, Y. MiR-574-5P, miR-1827, and miR-4429 as Potential Biomarkers for Schizophrenia. J. Mol. Neurosci. 2022, 72, 226–238. [Google Scholar] [CrossRef]
  80. Fan, X.; Chen, G.; Ma, F.; Qi, B.; Liang, Y.; Gopng, P.; Meng, C. An lncRNA-miRNA-mRNA-ceRNA network regulates intervertebral disc degeneration: A bioinformatics study based on the dataset analysis. Gen. Physiol. Biophys. 2021, 40, 317–327. [Google Scholar] [CrossRef]
  81. Wang, F.; Li, Z.; Zhao, M.; Ye, W.; Wu, H.; Liao, Q.; Bu, S.; Zhang, Y. Circulating miRNAs miR-574-5p and miR-3135b are potential metabolic regulators for serum lipids and blood glucose in gestational diabetes mellitus. Gynecol. Endocrinol. 2021, 37, 665–671. [Google Scholar] [CrossRef] [PubMed]
  82. Hegewald, A.B.; Breitwieser, K.; Ottinger, S.M.; Mobarrez, F.; Korotkova, M.; Rethi, B.; Jakobsson, P.-J.; Catrhina, A.I.; Wähämaa, H.; Saul, M.J. Extracellular miR-574-5p Induces Osteoclast Differentiation via TLR 7/8 in Rheumatoid Arthritis. Front. Immunol. 2020, 11, 585282. [Google Scholar] [CrossRef] [PubMed]
  83. Berindan-Neagoe, I.; Monroig Pdel, C.; Pasculli, B.; Calin, G.A. MicroRNAome genome: A treasure for cancer diagnosis and therapy. CA Cancer J. Clin. 2014, 64, 311–336. [Google Scholar] [CrossRef] [PubMed]
  84. Cao, E.A.Z.; Qiu, J.; Yang, G.; Liu, Y.; Luo, W.; You, L.; Zheng, L.; Zhang, T. MiR-135a biogenesis and regulation in malignancy: A new hope for cancer research and therapy. Cancer Biol. Med. 2020, 17, 569–582. [Google Scholar] [CrossRef]
  85. Swensen, S.J.; Jett, J.R.; Hartman, T.E.; Midthun, D.E.; Mandrekar, S.J.; Hillman, S.L.; Sykes, A.-M.; Aughenbaugh, G.L.; Bungum, A.O.; Allen, K.L. CT screening for lung cancer: Five-year prospective experience. Radiology 2005, 235, 259–265. [Google Scholar] [CrossRef]
  86. Han, Z.; Li, Y.; Zhang, J.; Guo, C.; Li, Q.; Zhang, X.; Lan, Y.; Gu, W.; Xing, Z.; Liang, L.; et al. Tumor-derived circulating exosomal miR-342-5p and miR-574-5p as promising diagnostic biomarkers for early-stage Lung Adenocarcinoma. Int. J. Med. Sci. 2020, 17, 1428–1438. [Google Scholar] [CrossRef]
  87. Peng, H.; Wang, J.; Li, J.; Zhao, M.; Huang, S.-K.; Gu, Y.-Y.; Li, Y.; Sun, X.-J.; Yang, L.; Luo, Q.; et al. A circulating non-coding RNA panel as an early detection predictor of non-small cell lung cancer. Life Sci. 2016, 151, 235–242. [Google Scholar] [CrossRef]
  88. Foss, K.M.; Sima, C.; Ugolini, D.; Neri, M.; Allen, K.E.; Weiss, G.J. miR-1254 and miR-574-5p: Serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J. Thorac. Oncol. 2011, 6, 482–488. [Google Scholar] [CrossRef] [Green Version]
  89. Zhou, J.; Shao, G.; Chen, X.; Yang, X.; Huang, X.; Peng, P.; Ba, Y.; Zhang, L.; Jehangir, T.; Bu, S.; et al. miRNA 206 and miRNA 574-5p are highly expression in coronary artery disease. Biosci. Rep. 2015, 36, e00295. [Google Scholar] [CrossRef]
  90. Boileau, A.; Cardenas, C.L.L.; Courtois, A.; Zhang, L.; Rodosthenous, R.S.; Das, S.; Sakalihasan, N.; Michel, J.-B.; Lindsay, M.E.; Devaux, Y. MiR-574-5p: A Circulating Marker of Thoracic Aortic Aneurysm. Int. J. Mol. Sci. 2019, 20, 3924. [Google Scholar] [CrossRef]
  91. Zheng, D.; Ding, Y.; Ma, Q.; Zhao, L.; Guo, X.; Shen, Y.; He, Y.; Wei, W.; Liu, F. Identification of Serum MicroRNAs as Novel Biomarkers in Esophageal Squamous Cell Carcinoma Using Feature Selection Algorithms. Front. Oncol. 2018, 8, 674. [Google Scholar] [CrossRef] [Green Version]
  92. Huang, S.-K.; Luo, Q.; Peng, H.; Li, J.; Zhao, M.; Wang, J.; Gu, Y.-Y.; Li, Y.; Yuan, P.; Zhao, G.-H.; et al. A Panel of Serum Noncoding RNAs for the Diagnosis and Monitoring of Response to Therapy in Patients with Breast Cancer. Med. Sci. Monit. 2018, 24, 2476–2488. [Google Scholar] [CrossRef] [PubMed]
  93. Li, J.; Tiwari, A.; Mirzakhani, H.; Wang, A.; Kho, A.; McGeachie, M.; Litonjua, A.; Weiss, S.; Tantisira, K. Circulating MicroRNA: Incident Asthma Prediction and Vitamin D Effect Modification. J. Pers. Med. 2021, 11, 307. [Google Scholar] [CrossRef] [PubMed]
  94. Boileau, A.; Somoza, A.S.; Dankiewicz, J.; Stammet, P.; Gilje, P.; Erlinge, D.; Hassager, C.; Wise, M.P.; Kuiper, M.; Friberg, H.; et al. Circulating Levels of miR-574-5p Are Associated with Neurological Outcome after Cardiac Arrest in Women: A Target Temperature Management (TTM) Trial Substudy. Dis. Markers 2019, 2019, 1802879. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  95. Liu, S.; Zhao, L.; Zhang, L.; Qiao, L.; Gao, S. Downregulation of miR-574-5p inhibits HK-2 cell viability and predicts the onset of acute kidney injury in sepsis patients. Ren. Fail. 2021, 43, 942–948. [Google Scholar] [CrossRef] [PubMed]
  96. Wang, H.; Meng, K.; Chen, W.; Feng, D.; Jia, Y.; Xie, L. Serum miR-574-5p: A prognostic predictor of sepsis patients. Shock 2012, 37, 263–267. [Google Scholar] [CrossRef]
Biomolecules 13 00040 g001 550
Figure 1. The biogenesis of miR-574-5p. miR-574-5p is first transcribed by RNA polymerase II and mirtrons are obtained. Mirtrons can be spliced and debranched into pre-miRNA hairpin mimics that bypass Drosha cleavage. Debranched mirtrons access the canonical miRNA pathway during nuclear export, and are then cleaved by Dicer and loaded onto argonaute proteins. In the cytoplasm, Dicer endoribonuclease cleaves the ring structure to produce mature miR-574-5p. Human miR-574-5p (has-miR-574-5p) is encoded by mir574 (gene ID: 693159), which is located on the human chromosome 4p14. The sequence and nucleotide sequence of miR-574-5p gene are shown in the figure.
Figure 1. The biogenesis of miR-574-5p. miR-574-5p is first transcribed by RNA polymerase II and mirtrons are obtained. Mirtrons can be spliced and debranched into pre-miRNA hairpin mimics that bypass Drosha cleavage. Debranched mirtrons access the canonical miRNA pathway during nuclear export, and are then cleaved by Dicer and loaded onto argonaute proteins. In the cytoplasm, Dicer endoribonuclease cleaves the ring structure to produce mature miR-574-5p. Human miR-574-5p (has-miR-574-5p) is encoded by mir574 (gene ID: 693159), which is located on the human chromosome 4p14. The sequence and nucleotide sequence of miR-574-5p gene are shown in the figure.
Biomolecules 13 00040 g001
Biomolecules 13 00040 g002 550
Figure 2. Pathological processes of miR-574-5p in tumorigenesis. Dysregulated miR-574-5p is present in all pathological processes of tumorigenesis, including cancer cell proliferation, migration, invasion, metastasis, apoptosis, epithelial-mesenchymal transition, and angiogenesis. The figure lists some of the roles miR-574-5p plays as a tumor suppressor or as an oncogene in various types of tumors.
Figure 2. Pathological processes of miR-574-5p in tumorigenesis. Dysregulated miR-574-5p is present in all pathological processes of tumorigenesis, including cancer cell proliferation, migration, invasion, metastasis, apoptosis, epithelial-mesenchymal transition, and angiogenesis. The figure lists some of the roles miR-574-5p plays as a tumor suppressor or as an oncogene in various types of tumors.
Biomolecules 13 00040 g002
Biomolecules 13 00040 g003 550
Figure 3. The role of miR-574-5p in non-cancerous diseases. miR-574-5p plays an important role in a wide range of non-cancerous diseases, including cardiovascular, respiratory, acute digestive tract, urinary system, and neurological diseases, among others. The figure illustrates that miR-574-5p directly acts on target cells or indirectly regulates the expression of target genes through signaling pathways, thus promoting or inhibiting the occurrence and development of diseases.
Figure 3. The role of miR-574-5p in non-cancerous diseases. miR-574-5p plays an important role in a wide range of non-cancerous diseases, including cardiovascular, respiratory, acute digestive tract, urinary system, and neurological diseases, among others. The figure illustrates that miR-574-5p directly acts on target cells or indirectly regulates the expression of target genes through signaling pathways, thus promoting or inhibiting the occurrence and development of diseases.
Biomolecules 13 00040 g003
Table
Table 1. The regulation of miR-574-5p in cancer.
Table 1. The regulation of miR-574-5p in cancer.
DiseasePathologyAuthorTargetProcessFunctionExpression of miRImpactPathways
Lung cancersmall-cell lung cancer (SCLC)Zhou Rui 2015PTPRU, EPAS1metastasismiR-574-5p significantly enhances the metastasis of SCLC and participates in β-catenin signaling by Suppressing protein tyrosine phosphatase receptor type U (PTPRU) or endothelial PAS domain protein 1 (EPAS1).↑↓Wnt/β-catenin
non-small cell lung cancer (NSCLC)Saul et al., 2019CUGBP1induce mPGES-1 expression, PGE formation and tumor growthmiR-574-5p induces microsomal prostaglandin E synthase-1 (mPGES-1) expression by preventing CUGBP1 binding to its 3’UTR, leading to enhanced alternative splicing and generation of an mPGES-1 3’UTR isoform, increased mPGES-1 protein expression, and PGE formation↑↓NA
Emmerich 2020CUGBP1induce mPGES-1 expression, PGE formation and tumor growthmiR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction.↑↓NA
Zhou Rui 2016PTPRUcell migration and invasionmiR-574-5p enhances the tyrosine phosphorylation of β-catenin by repressing PTPRU expression and promotes the migration and invasion of NSCLC cells.↑↓Wnt/β-catenin
Hua Peng 2016nonediagnostic biomarkermiR-574-5p can serve as a convenient tool for early NSCLC diagnosis.↓NANA
Kristen M. 2011nonediagnostic biomarkerhsa-miR-574-5p is significantly increased in early-stage NSCLC samples.↑NANA
lung adenocarcinomaZhijun Han 2020nonediagnostic biomarkerCirculating exosomal miR-574-5p has potential to serve as novel diagnostic biomarkers for early-stage LA.↑NANA
Gastric cancernot-mentionedZhengyi Zhang 2019QKI6cell proliferation, growth and invasionThe increase in miR-574-5p/-3p ratio, named miR-574 arm-imbalance, is partially due to the dynamic expression of their highly complementary targets in gastric carcinogenesis; the arm-imbalance of miR-574 is in turn involved and further promotes gastric cancer progression.↑↓NA
not-mentionedShu Zhang, 2020PTPN3angiogenesismiR-574-5p in gastric cancer cells promotes angiogenesis via enhancing phosphorylation of p44/42 MAPKs by miR-574-5p inhibition of PTPN3 expression.↑↓MAPKs
not-mentionedJianming Li 2014nonemaintaining the stemness
of the gastric CSCs		miR-574-5p shows decreased expression pattern in gastric CSCs↓↑NA
Colorectal cancernot-mentionedShunlong Ji 2012Qki6/7cell proliferation, migration, invasion, differentiation and cell cycleUpregulation of miR-574-5p decreases the expression of Qk6/7 to inhibit b-catenin mRNA and protein expression and inhibit B-catenin /Wnt signal transduction in CRC cells↑↓Wnt/β-catenin
colorectal cancer liver metastasisZhe Cui, 2014MACC-1liver metastasishsa-miR-574-5p plays a suppressive role in colorectal cancer liver metastasis by negatively directing MACC-1 expression↓↑NA
Esophageal squamous cell carcinoma not-mentionedDeqiang Zheng 2019nonediagnostic and prognostic biomarkermiR574 can distinguish ESCC patients from healthy controls. Moreover, the classifying performance of the miRNA panel can discriminate healthy controls from patients with ESCC stage I-II (AUC > 0.76) and patients with ESCC stage III-IV (AUC > 0.80).↑↓NA
not-mentionedMIAO YANG 2013nonediagnostic biomarkerhsa-miR-574-5p is upregulated in tumor tissues; multiple regression analysis revealed the aberrant expression of hsa-miR-574-5p increases the risk of esophageal cancer.↑↓NA
not-mentionedJie Li 2021SMAD4cell proliferation and apoptosismiR-574-5p represses the abundance of ESCC cells, which leads to booming cell growth of ESCC.↑↓NA
not-mentionedGuo Liang Han 2020ZNF70cell proliferation and apoptosismiR-574-5p serve as a tumor promoter regulating cells proliferation and apoptosis in ESCC through and MAPK pathways. Furthermore, ZNF70 has been proven to be a functional target for miR-574-5p to regulate cells proliferation and apoptosis↑↓MAPKs
Breast cancertriple-negative breast cancerKE-JING ZHANG 2020BCL11A, SOX2cell proliferation, migration and EMTmiR-574-5p attenuates proliferation, migration, and EMT in triple-negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis.↓↑NA
not-mentionedSheng-kai Huang 2018nonediagnostic and prognostic biomarkermiR-574-5p might represent a serum biomarker panel with potential in the diagnosis of breast cancer.↑ NA
estrogen receptor (ER) positive breast cancer Margherita Piccolella 2021HSPB8cell proliferation and migrationDownregulation of miR-574-5p, which binds to HSPB8 ORF, causes increased expression of HSPB8 protein and the proliferation and migration of ER+BC MCF-7 cells.↓↑NA
Thyroid cancernot-mentionedZhejia Zhang 2018QKIcell cycle and migration miR-574-5p mediates the cell cycle and apoptosis in thyroid cancer cells via Wnt/β-catenin signaling by repressing the expression of Quaking proteins.↑↓Wnt/β-catenin
not-mentionedZhe-JiaZhang 2020FOXN3cell migration, proliferation, invasion and apoptosis miR-574-5p directly targets FOXN3 in thyroid cancer cells, which activates Wnt/β-catenin singling pathway and promotes cell migration, proliferation, invasion and apoptosis↑↓(pathway activated)Wnt/β-catenin
papillary thyroid carcinoma (PTC) Xiaoming Wang 2017SCAIcell proliferation and migrationPTCSC3 absorbs miR-574-5p, and miR-574-5p targets SCAI; SCAI can regulate the activity of Wnt/β-catenin. PTCSC3/miR-574-5p regulates the activity of Wnt/β-catenin via SCAI and mediates cell proliferation and migration of PTC-1.↑↓Wnt/β-catenin and non-coding RNA
Chordomanot-mentionedEmre Can Tuysuza 2019MYCBPcell viability, apoptosis, migration and invasionmiR-574-5p targets MYCBP and inhibits the invasive and migratory phenotype; miR-574-5p decreases viability and increases apoptosis in U-CH1 cells while it has no effect on both viability and apoptosis in MUG-Chor1 cells.↓↑NA
Head and neck squamous cell carcinoma chemotherapy-induced cell death and nodal metastasisMarisa Meyers-Needham 2011CerS1-2cell proliferation and growthInhibition of HDAC1 and siRNA-mediated knockdown of miR-574-5p reconstitutes CerS1-2 expression and C18-ceramide generation, which subsequently inhibits cancer cell proliferation.↑↓NA
Table
Table 2. The regulation of miR-574-5p in other diseases.
Table 2. The regulation of miR-574-5p in other diseases.
Disease TypeAuthorTargetDiseaseFunctionExpression of miR in DiseaseImpactTherapeutic Significance
Cardiovascular diseasesJianqing Zhou 2016not mentionedCoronary artery disease (CAD)miR-574-5p is significantly upregulated in CAD patients, which indicates that it has great potential to provide sensitive and specific diagnostic value for CAD.↑NAbiomarker
Lai Zhongmeng 2018ZDHHCCADUpregulation of miR-574-5p enhances cell proliferation and suppresses apoptotic processes in VSMCs through targeting ZDHHC14, suggesting that miR-574-5p is a CAD-related factor that may serve as a potential molecular target for CAD treatment.↑↓potential target
Wu Jiangbin2021FAM2104AHeart failuremiR-574 targets FAM210A and modulates mitochondrial-encoded protein expression, which may contribute to cardiac remodeling in heart failure.↑↑protective role
CuJun 2020ARID3ACardiac fibrosis after myocardial infarction (MI)miR-574-5p directly targets ARID3A to promote fibroblast-to-myofibroblast differentiation of TGF-β-induced human cardiac fibroblasts (HCFs)↑↓potential target
Adeline Boileau 2019not mentionedCardiac arrestmiR-574-5p is associated with neurological outcome after cardiac arrest in women.↑NAbiomarker
Boileau 2019not mentionedThoracic aortic aneurysm (TAA)miR-574-5p may act as a paracrine mediator in TAA pathogenesis and could be secreted in response to Ang II (further research needed)↑ biomarker
Respiratory diseasesBinchan He 2020HMGB1Acute respiratory distress syndrome (ARDS)miR-574 targets HMGB1 to inhibit the inflammatory response via suppression of TLR4/NF-Κb signaling pathway and the NLRP3 inflammasome↑↑protective role
LiJiang 2021not mentionedAsthmahsa-miR-574-5p is a potential mediator and biomarker of asthma and has excellent prognostic power.↑NAbiomarker
LI 2017not mentionedObstructive sleep apneamiR-574-5p is significantly upregulated in OSA↑NANA
Digestive system diseaseWu Wenyu 2021HBV polymerase
mRNA		Chronic hepatitis B (CHB)hsa-miR574-5p downregulates the expression of HBV polymerase mRNA and pgRNA by direct binding to nucleotides 2750-2757↑↑protective role; potential target
Tan Youwen 2015not mentionedChronic hepatitis BmiR-574-5p could be a surrogate marker for chronic hepatitis B with persistently normal alanine aminotransferase (ALT)↑NAbiomarker?
ZhouXia 2021α-SMA, COL1A1Liver cirrhosismiR-574-5p in serum exosomes transfers to HSC to activate HSC, which is relevant to liver cirrhosis.↑↓potential target
Neurological disordersTingting Ku 2017BACE1NeuroinflammationmiR-574-5p directly binds to the 3’ UTR of BACE1 to reduce its role of impairing functional synaptic integrity and spatial learning and memory.
Overexpression of miR-574-5p in the hippocampal region decreases BACE1 expression, restores synaptic function, and improves spatial memory and learning following PM2.5 exposure.		↓↑protective role
Freischmidt 2013not mentionedAmyotrophic lateral sclerosis (ALS)TDP-43 binding serum miRNA levels are candidates for an easily accessible biological measure of TDP-43 dysfunction in ALS↓NANA
Xiaobo Yang 2021SOD2Acute ischemic stroke (AIS)circPHKA2 protects HBMEC from OGD-induced neurovascular injuries by controlling SOD2 via sponging miR-574-5p.↑↓NA
Urinary system diseasesGuoHang 2021C7Diabetic NephropathymiR-574-5p can negatively regulate expression of C7. Elevated C7 gene expression level in MES is regulated by miR-494-3p and miR-574-5p in early diabetic nephropathy↓↑NA
Shanshan Liu 2021HK-2 (cell)Acute kidney injury in sepsisDownregulation of miR-574-5p inhibits HK-2 cell viability and predicts the onset of acute kidney injury in sepsis patients.↓↑biomarker
OthersLip 2020MKI67PreeclampsiamiR-574-5p and miR-1972 decrease the proliferation (probably via decreasing MKI67) and/or migration as well as the tube-formation capacity of endothelial cells↑↓potential target
XuYetao 2020JDP2PreeclampticmiR-574 can directly bind to both AGAP2 AS1 and JDP2, and AGAP2 AS1 regulates JDP2 expression via the AGAP2 AS1/miR 574 axis in trophoblasts↑↓potential target
Belarbi 2018EBF1Obesity/diabetesmiR-574-5p is associated with human adipose morphology and regulates EBF1 expression in white adipose tissue↑↓NA
WangFuyan 2021Some predicted targets are associated with the metabolism of glucose and lipids and the insulin signaling pathway.Gestational diabetes mellitus (GDM)The expression of miR-574-5p is significantly correlated with levels of blood glucose and LDL-C, which indicates that miR-574-5p may serve as a metabolic regulator of glucose and lipids for GDM.↓NAbiomarker
Davarinejad 2021not mentionedSchizophreniahsa-miR-574-5P is suggested as a potential biomarker for diagnosis of schizophrenia.↑NAbiomarker
Hegewald 2020TLR 7/8Rheumatoid ArthritisExtracellular miR-574-5p induces osteoclast differentiation via TLR 7/8 in rheumatoid arthritis.↑↓potential target
Xutao Fan 2021P3H2Ontervertebral disc degeneration (IDD)has-miR-574-5p can suppress the expression on P3H2 in IDD progression↓↑NA
Wang, Huijuan 2012not mentionedSepsisserum miR-574-5p is correlated with the death of sepsis patient↓ in nonsurvivorsNAbiomarker
Sabetian 2021ACE2Male infertility in COVID-19Downregulation of miR-574-5p may lead to an increase in ACE2 expression related to male infertility in COVID-19↓↑NA
Table
Table 3. Recent clinical applications of miR-574-5p.
Table 3. Recent clinical applications of miR-574-5p.
CatagoryAuthorDiseaseOriginSampleTendencyDiagnosisPrognosisCombination
cancerZhijun Han 2020lung adenocarcinomaserum 7 early-stage lung adenocarcinoma patients including pre-operation and post-operation vs. 7 heathy controls↑YesYeswith miR-342-5p
Zhou Rui 2015small-cell lung cancer (SCLC)serum and tissuea set of 72 SCLC patients (22 limited disease vs. 50 extensive disease)↑NAYesnone
Hua Peng 2016non-small cell lung cancer (NSCLC)serumtraining set: 36 NSCLCs vs. 36 controls
validation set: 120 NSCLCs vs. 71 controls		↓YesYesa four non-coding RNAs panel (miR-1254, miR-485-5p, miR-574-5p, and MALAT1)
Kristen M. 2011serumtraining set: 11 early-stage NSCLCs vs. 11 controls
validation set: 22 early-stage NSCLCs vs. 31 controls		↑YesNAwith hsa-miR-1254
Xiao-Rong Yang 2021plasma exosome30 EGFR/ALK positive NSCLC patients (16 phase IV patients with bone metastasis and 14 without bone metastasis) vs. 14 healthy donors↓NAYeswith miR-328-3p and miR-423-3p (all belong to cluster B)
Sheng-kai Huang 2018breast cancerserumtraining set: 30 breast cancer patients vs. 30 controls
validation set: 128 breast cancer patients vs. 77 controls		↑YesYes (treatment matters)A panel of ncRNAs, (let-7a, miR-155, miR-574-5p, and MALAT1)
Deqiang Zheng 2019esophageal squamous cell carcinoma (ESCC)serum52 ESCC patients vs. 52 age- and sex-matched controls↑YesYeswith miR-16-5p, miR-451a
MIAO YANG 2013tissuetumor tissue and non-tumor tissue from 138 ESCC patients↑YesNAa set of RNA profiles (hsa-miR-338-3p, hsa-miR-139-5p, hsa-miR-574-5p, and hsa-miR-601)
non-cancerJianqing Zhou 2016coronary artery disease (CAD)plasma67 CAD patients vs. 67 healthy controls↑YesNAwith miR-206
Adeline Boileau 2019cardiac arrestserum590 cardiac arrest patients↑NAyes (neurological outcome in women)none
Boileau 2019thoracic aortic aneurysm (TAA)serum and tissue19 TAA patients and 19 controls; 28 TAA patients compared to 20 controls↑ in serum and ↓ in tissueYesNAnone
LiJiang 2021asthmaplasmatraining set: 75 participants with recurrent wheezing at 3 years old from the Vitamin D Antenatal Asthma Reduction Trial
validation set: 20 participants in Project Viva with recurrent wheezing at 3 years old		↑NAYeswith vitamin D level; a set of circulating miRNA including hsa-miR-151a-5p
Shanshan Liu 2021acute kidney injury in sepsisserum136 patients with sepsis (58 developed AKI during hospitalization)↓NAYes (acute kidney injury)none
Wang, Huijuan 2012sepsisserumtraining set: 12 surviving and 12 nonsurviving sepsis patients
validation set: 66 surviving and 52 nonsurviving sepsis patients		↑ in survivorsNAYes (death)with miR-297
WangFuyan 2021gestational diabetes mellitus (GDM)plasma53 women with GDM and 46 normal pregnant women.↓YesNAwith miR-3135b
Davarinejad 2021Schizophrenia (SCZ)whole bloodtraining set: 2 mRNA expression arrays (GSE93987 and GSE38485) and 1 miRNA array (GSE54914) validation set: 40 SCZ patients↑YesNAwith hsa-miR-1827 and hsa-miR-4429 a
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Huang, W.; Zhao, Y.; Xu, Z.; Wu, X.; Qiao, M.; Zhu, Z.; Zhao, Z. The Regulatory Mechanism of miR-574-5p Expression in Cancer. Biomolecules 2023, 13, 40. https://doi.org/10.3390/biom13010040

AMA Style

Huang W, Zhao Y, Xu Z, Wu X, Qiao M, Zhu Z, Zhao Z. The Regulatory Mechanism of miR-574-5p Expression in Cancer. Biomolecules. 2023; 13(1):40. https://doi.org/10.3390/biom13010040

Chicago/Turabian Style

Huang, Wei, Yifan Zhao, Zhengyi Xu, Xiaoyue Wu, Mingxin Qiao, Zhou Zhu, and Zhihe Zhao. 2023. "The Regulatory Mechanism of miR-574-5p Expression in Cancer" Biomolecules 13, no. 1: 40. https://doi.org/10.3390/biom13010040

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop